$heff's $tation of $tocks & $olid DD

[cabos_tacos]

ABBV $67.48

bVie's (NYSE: ABBV ) shares have risen by 35% in the past year, and are now pushing through their all-time highs in recent sessions. Despite this rapid price appreciation, I think AbbVie is on track to continue its upward trajectory for a good while longer, and Wall Street apparently shares my view. In the third quarter, top notch hedge funds like Paulson & Co. and Soros Fund Management, among others, took out huge positions in the drugmaker, upping overall institutional ownership by roughly 12%.


http://www.fool.com/investing/general/2014/11/24/3-biotech-stocks-that-could-soar-even-higher.aspx

AbbVie’s (ABBV) cocktail hepatitis C virus (:HCV) treatment is now closer to EU approval with the European Medicines Agency’s (EMA.TO) European Committee for Medicinal Products for Human Use (CHMP) providing positive opinions regarding the marketing of the experimental treatment.

AbbVie is looking to get the investigational, all-oral, interferon-free treatment of Viekirax (ombitasvir/paritaprevir/ritonavir) plus Exviera (dasabuvir) approved for use with or without ribavirin (RB.V) in patients with genotype 1 (GT1) and genotype 4 (GT4) chronic HCV infection.

http://finance.yahoo.com/news/abbvies-hcv-cocktail-treatment-closer-230001554.html